News List
PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials
2023-01-10
Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1
adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market
2022-12-16
2022.12.12, the US FDA announced the approval of Mirati Therapeutics' oral KRAS G12C inhibitor a
New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!
2022-11-26
Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel a
HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!
2022-10-29
AstraZeneca (AstraZeneca) recently reported positive, high-level results from its phase II trial of
Huatangning, the world's first new hypoglycemic drug was approved
2022-10-10
Beijing, Oct. 9, 2022 -- Bayer announced that the global initiative for state and drug administratio
Haihe Pharmaceuticals' Paclitaxel Oral Solution China Marketing Authorization Application Officially Accepted
2022-09-15
On September 13, 2022, Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and South Ko
Using artificial intelligence to detect Parkinson's disease by reading people's breathing patterns
2022-08-24
Parkinson's disease is notoriously difficult to diagnose because it relies primarily on the onse
Targeting specific DNA of Plasmodium may be effective in treating human malaria infection
2022-07-29
Targeting a parasite's DNA could be a more effective way to combat malaria, new research from th
Vijoice is the first FDA-approved PRS treatment
2022-07-07
2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera
Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib
2022-06-14
Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03